Publications by authors named "C Lademacher"

Aims: To evaluate the efficacy and safety of mirabegron in children and adolescents (aged 3 to <18 years) with neurogenic detrusor overactivity (NDO) using clean intermittent catheterization.

Methods: In this open-label, multicenter, baseline-controlled, Phase III study (NCT02751931), participants received once-daily mirabegron at an adult dose equivalent of 25 mg. Dose was increased to 50 mg equivalent unless there were safety/tolerability concerns.

View Article and Find Full Text PDF

Isavuconazole, administered as the water-soluble prodrug isavuconazonium sulfate, is a new triazole agent used to treat invasive fungal infections. This phase 1 study evaluated the pharmacokinetics (PK), safety, and tolerability of isavuconazole in 46 immunocompromised pediatric patients, stratified by age (1 to <6 [intravenous (i.v.

View Article and Find Full Text PDF
Article Synopsis
  • Polycystic ovary syndrome (PCOS) is a common endocrine disorder that causes fertility issues primarily due to high androgen levels.
  • A study tested the effectiveness and safety of the NK3 receptor antagonist fezolinetant in reducing testosterone levels in women with PCOS.
  • Results showed that fezolinetant significantly lowered total testosterone and improved the LH-to-FSH ratio, indicating its potential as a treatment for PCOS-related hyperandrogenism, with no major safety concerns.
View Article and Find Full Text PDF

Background: Cytomegalovirus (CMV) is a complication of allogeneic haematopoietic cell transplantation (allo-HCT). ASP0113, a DNA-based vaccine, contains two plasmids encoding human CMV glycoprotein B and phosphoprotein 65 (pp65). We assessed ASP0113 in CMV-seropositive allo-HCT recipients.

View Article and Find Full Text PDF
Article Synopsis
  • International guidelines support the use of menopausal hormone therapy (HT) for women under 60 or within 10 years of menopause, but safety concerns about cancer and other risks have led to decreased usage.
  • There is a demand for effective non-hormonal therapies to alleviate menopausal vasomotor symptoms (VMS), such as hot flashes.
  • Fezolinetant, a neurokinin-3 receptor (NK3R) antagonist, is in advanced clinical development and has shown promising results in reducing VMS frequency and severity, providing a potential non-hormonal treatment option.
View Article and Find Full Text PDF